Category: Stents
Stents
OrbusNeich reports complete strut and neotintimal coverage of its Genous Bio-engineered R stent 26 days after doctors implanted the device in a heart attack victim.
A patient implanted with OrbusNeich Medical Inc.'s Genous Bio-engineered R stents showed 100 percent strut and complete neotintimal coverage 26 days after the procedure, the company said.*
The patient, a 62-year-old male, received two 2.5 mm diameter models of the stents after doctors diagnosed an anterior ST-elevation myocardial infarction — a heart attack.
Eamonn Hobbs, CEO of Delcath Systems, is tapped to be Irish stent maker Capella Inc.'s chairman of the board.
Eamonn Hobbs took over as board chairman for Irish stent-maker Capella Inc.
Hobbs is CEO of Delcath Systems Inc. (NSDQ:DCTH), a New York-based manufacturer of arterially administered cancer treatments, and was CEO and co-founder of AngioDynamics (NSDQ:ANGO). Hobbs fills the position of former Capella chairman Dr. Wolfgang Oster, a managing partner at PolyTechnos Venture-Partners GmbH.
Abbott Laboratories lays off 120 workers in California, the majority of whom worked in the company's stent manufacturing operation there.
Abbott Laboratories (NYSE:ABT) laid off 120 workers from its California stent-making operation.
The Abbott Park, Ill.-based company laid off 101 workers from its Temecula and Murrieta vascular stent manufacturing facilities in the Golden State. The remaining 19 workers were let go from the company's Santa Clara, Calif., location.
Abbott spokesman Jonathon Hamilton wrote in an emailed statement that the layoffs were "part of its regular business review process."
A federal judge in Boston throws out a class action securities lawsuit accusing Boston Scientific Corp. of misleading investors about problems with its Taxus stent that led to a partial recall in 2004.
A federal judge in Boston tossed a class action securities lawsuit filed against Boston Scientific Corp. (NYSE:BSX) accusing the company of misleading investors about problems with its Taxus Express drug-eluting stent.
OrbusNeich Medical Inc. wins a stent patent from the U.S. Patent & Trademark Office and promptly moves to amend its infringement lawsuit against Boston Scientific Corp. to include its new intellectual property.
OrbusNeich Medical Inc. wasted no time after winning a new patent from the U.S. Patent & Trademark Office, filing a motion to amend a patent infringement lawsuit against Boston Scientific Corp. (NYSE:BSX) to include its new intellectual property.
The USPTO granted the Hong Kong-based firm, which has its U.S. headquarters in Ft. Lauderdale, Fla., a patent covering a "Stent with Helical Elements," according to a press release. The patent, granted March 23, covers an expandable stent with "a plurality of helical segments," according to the release.
Boston Scientific Corp. appeals a Delaware judge's ruling that a pair of Cordis Corp. stent patents are, after all, enforceable, which overturned her prior decision that the patents were not enforceable.
Boston Scientific Corp. (NYSE:BSX) is looking to run a double-reverse with its appeal of a judge's decision in its long-running war with Johnson & Johnson's (NYSE:JNJ) Cordis Corp. over stent patents.
The Natick, Mass.-based medical device maker filed an appeal with the U.S. Court of Appeals for the Federal Circuit seeking to reverse an August 2009 ruling, which itself reversed a prior decision, regarding the enforceability of a pair of Cordis Corp. patents.
Johnson & Johnson isn't the only party appealing a Delaware judge's ruling that four of its patents are invalid, as Boston Scientific Corp. cross-appeals despite winning the case's last round.
Boston Scientific Corp. (NYSE:BSX) may have won the most recent round in its stent patents war with Johnson & Johnson (NYSE:JNJ), but that didn't stop the Natick, Mass.-based devices giant from cross-appealing a Delaware judge's ruling.
The patents in question are at the heart of complicated legal wrangling involving Boston Scientific, its New Brunswick, N.J.-based rival and competitor/partner Abbott (NYSE:ABT). The dispute centers around Boston Scientific's Promus stent, a private-label version of Abbott's Xience V stent, and the JNJ subsidiary Cordis Corp.'s Cypher.
